| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3.1 | 0.0 |
| Net income | -37.7 | -24.6 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Crescent Biopharma, Inc.: key numbers
- Share price
- $13.50Close, Nov 16
- Market cap
- $525M
- Shares outstanding
- 38.9MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Crescent Biopharma, Inc.
All →Crescent Biopharma Financial Results
Crescent Biopharma reported Q3 2026 financial results and provided clinical updates on its lead programs, including the completion of dose escalation for CR-001 in the Phase 1/2 ASCEND trial. The company expects initial monotherapy data for CR-001 in Q1 2027 and highlighted that over 2,000 patients are expected to be dosed across its portfolio by mid-2027.
- Counterparty
- Kelun-Biotech
“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027.”
Joshua Brumm, chief executive officer of Crescent
“The team’s strong execution has positioned us for several meaningful clinical data readouts in 2027, beginning in the first quarter with monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients, followed by initial standard of care chemotherapy combination data from multiple tumor types.”
Joshua Brumm, chief executive officer of Crescent
Crescent Biopharma Business Update
Crescent Biopharma provided a comprehensive clinical pipeline update, including the commencement of chemotherapy combination cohorts in its Phase 1/2 ASCEND trial for CR-001. The company also announced the initiation of combination studies with Kelun-Biotech and set expectations for initial monotherapy data readouts in Q1 2027.
- Counterparty
- Kelun-Biotech Biopharmaceutical Co., Ltd.
Crescent Biopharma CMO Ellie Eunkyung Im Sells $11.2K of Stock
Ellie Eunkyung Im, CMO, sold 623 shares of Crescent Biopharma, Inc. at $17.90 a share, worth $11.2K in total on Sep 16, 2026. Shares held after the trade: 21,446 (-2.8%).
- Value
- $11.2K
- Shares
- 623
- Price
- $17.90
- Role
- CMO
- Holding change
- -2.8%
- Trade date
- Sep 16, 2026
Crescent Biopharma President and COO Jonathan McNeill Sells $77.2K of Stock
Jonathan McNeill, President and COO, sold 4,570 shares of Crescent Biopharma, Inc. at $16.71 to $17.90 a share (average $16.90) in 2 transactions, worth $77.2K in total between Sep 16, 2026 and Sep 18, 2026. Shares held after the trade: 134,588 (-2.8%).
- Value
- $77.2K
- Shares
- 4,570
- Average price
- $16.90
- Role
- President and COO
- Holding change
- -2.8%
- Trade date
- Sep 16, 2026 to Sep 18, 2026
Crescent Biopharma CFO Richard William Scalzo Sells $10.2K of Stock
Richard William Scalzo, CFO, sold 568 shares of Crescent Biopharma, Inc. at $17.90 a share, worth $10.2K in total on Sep 16, 2026. Shares held after the trade: 19,730 (-2.8%).
- Value
- $10.2K
- Shares
- 568
- Price
- $17.90
- Role
- CFO
- Holding change
- -2.8%
- Trade date
- Sep 16, 2026
Crescent Biopharma CEO Joshua T. Brumm Sells $160K of Stock
Joshua T. Brumm, CEO, sold 9,447 shares of Crescent Biopharma, Inc. at $16.71 to $17.90 a share (average $16.91) in 2 transactions, worth $160K in total between Sep 16, 2026 and Sep 18, 2026. Shares held after the trade: 271,765 (-2.8%).
- Value
- $160K
- Shares
- 9,447
- Average price
- $16.91
- Role
- CEO
- Holding change
- -2.8%
- Trade date
- Sep 16, 2026 to Sep 18, 2026